Expanding Therapeutic Horizons: Targeting Non-V600 BRAF Mutations in Solid Tumors

In this commentary, an expert addresses the importance of targeting non-V600 BRAF alterations in cancer and the emerging data on investigational agents targeting these alterations in patients.

Share

Program Content

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by an educational grant from Kinnate Biopharma.

Kinnate Biopharma